Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.CRISPR gene editing technology offers precise DNA modification for treating genetic diseases like sickle cell disease. Recent FDA approval marks a milestone, though challenges in safety and delivery remain for broader applications.
Area Of Science
- Genetics and Genomics
- Biotechnology
- Molecular Biology
Background
- Genome editing has advanced significantly, with CRISPR-Cas9 technology revolutionizing genetic modification.
- CRISPR-Cas9 enables precise RNA-guided targeting and editing of specific genes with high accuracy and efficiency.
- Clinical trials show promising results for genetic disorders such as sickle cell disease (SCD) and transfusion-dependent beta-thalassaemia (TDT).
Purpose Of The Study
- To examine the transformative role of CRISPR technologies in modifying human genetic and epigenetic codes.
- To provide a comprehensive focus on clinical applications of gene editing, particularly CRISPR-based therapies.
- To explore the potential and challenges associated with CRISPR technology in medicine.
Main Methods
- Review of CRISPR-Cas9 technology, including base editing and prime editing approaches.
- Analysis of clinical trial data for gene editing in genetic diseases.
- Discussion of ongoing research into CRISPR applications for cancer, HIV, and other complex diseases.
Main Results
- FDA approval of Casgevy, the first CRISPR/Cas9-based gene therapy for SCD, utilizing edited autologous CD34+ hematopoietic stem cells.
- Demonstration of CRISPR technology's potential in treating inherited blood disorders.
- Identification of emerging research avenues for CRISPR in oncology, virology, and complex disease management.
Conclusions
- CRISPR technology represents a paradigm shift in genetic medicine, with significant clinical successes.
- Ongoing research continues to expand the therapeutic potential of gene editing.
- Challenges including off-target effects, delivery, long-term safety, scalability, and ethical considerations must be addressed for widespread adoption.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
Overview
Genetic engineering is the process of modifying an organism’s DNA to introduce new, desirable traits. Many organisms, from bacteria to plants and animals, have been genetically modified for academic, medical, agricultural, and industrial purposes. While genetic engineering has definite benefits, ethical concerns surround modifying humans and our food supply.
Scientists can Deliberately Modify an Organism’s Genome
Genetic engineering is possible because the genetic...
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...